Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Champions Oncology, Inc. CSBR
$4.30
+$0.04 (0.94%)
На 18:01, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
57895222.00000000
-
week52high
9.88
-
week52low
3.75
-
Revenue
49109000
-
P/E TTM
-22
-
Beta
0.87439400
-
EPS
-0.24000000
-
Last Dividend
0.00000000
-
Next Earnings Date
19 июл 2023 г. в 20:00
Описание компании
Champions Oncology, Inc. develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States. Its Tumorgraft Technology Platform is an approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. The company, through its Tumorgraft Technology Platform, provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice. It also offers Translational Oncology Solutions that utilizes its technology platform to assist pharmaceutical and biotechnology companies with their drug development process. The company provides Lumin Bioinformatics, a software platform and data tool that contains comprehensive information derived from research services and clinical studies, and sold on an annual subscriptions basis. The company markets its products through internet, word of mouth, and sales force to patients and physicians. The company was formerly known as Champions Biotechnology, Inc. and changed its name to Champions Oncology, Inc. in April 2011. Champions Oncology, Inc. was incorporated in 1985 and is headquartered in Hackensack, New Jersey.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Roth Capital | Buy | Buy | 15 мар 2021 г. |
| Benchmark | Speculative Buy | 18 ноя 2019 г. | |
| Roth Capital | Buy | 20 сент 2019 г. | |
| Janney Capital | Neutral | Buy | 24 июл 2019 г. |
| Craig-Hallum | Buy | 17 июл 2018 г. | |
| Janney Montgomery Scott | Neutral | Buy | 24 июл 2019 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| ACKERMAN JOEL | A | 0 | 16667 | 19 окт 2022 г. |
| ACKERMAN JOEL | A | 1460595 | 16667 | 19 окт 2022 г. |
| SIDRANSKY DAVID | D | 0 | 8333 | 12 окт 2022 г. |
| SIDRANSKY DAVID | D | 767043 | 3562 | 12 окт 2022 г. |
| SIDRANSKY DAVID | A | 770605 | 8333 | 12 окт 2022 г. |
| Breitfeld Philip P. | D | 0 | 8333 | 12 окт 2022 г. |
| Breitfeld Philip P. | D | 14638 | 3562 | 12 окт 2022 г. |
| Breitfeld Philip P. | A | 18200 | 8333 | 12 окт 2022 г. |
| TOBIN SCOTT R | D | 0 | 10000 | 12 окт 2022 г. |
| TOBIN SCOTT R | A | 30000 | 10000 | 12 окт 2022 г. |
Новостная лента
Champions Oncology, Inc. (CSBR) Reports Q3 Loss, Tops Revenue Estimates
Zacks Investment Research
15 мар 2023 г. в 18:19
Champions Oncology, Inc. (CSBR) delivered earnings and revenue surprises of -200% and 2.26%, respectively, for the quarter ended January 2023. Do the numbers hold clues to what lies ahead for the stock?
Champions Oncology to Announce Third Quarter Financial Results on Wednesday, March 15, 2023
Accesswire
13 мар 2023 г. в 08:30
HACKENSACK, NJ / ACCESSWIRE / March 13, 2023 / Champions Oncology, Inc. (NASDAQ:CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven pharmaco-pheno-multiomic integration, will report its financial and operational results for the third quarter ended January 31, 2023, on Wednesday, March 15, 2023, after market close. The company will host a conference call to discuss the results that day at 4:30 P.M.
Champions Oncology Trades At A Sufficient Discount To R&D Capacity
Seeking Alpha
29 янв 2023 г. в 00:37
CSBR runs a PDX bank. PDXs are mice models of human derived tumors. The company offers services to bio and pharma companies in pre clinical treatment testing. Its test have high predictive power for human results, without the associated cost.
Champions Oncology, Inc. (CSBR) Q2 2023 Earnings Call Transcript
Seeking Alpha
13 дек 2022 г. в 20:54
Champions Oncology, Inc. (NASDAQ:CSBR ) Q2 2023 Results Conference Call December 13, 2022 4:30 PM ET Company Participants Ronnie Morris - CEO David Miller - CFO Conference Call Participants Scott Henry - ROTH Capital Operator Good day, ladies and gentlemen, and welcome to the Champions Oncology Second Quarter Fiscal Year 2023 Earnings Call. At this time, all participants have been placed on a listen-only mode and the floor will be opened for you questions and comments after the presentation.
Champions Oncology to Announce Second Quarter Financial Results on Tuesday, December 13, 2022
Accesswire
09 дек 2022 г. в 16:30
HACKENSACK, NJ / ACCESSWIRE / December 9, 2022 / Champions Oncology, Inc. (CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven pharmaco-pheno-multiomic integration, will report its financial and operational results for the second quarter ended October 31, 2022, on Tuesday, December 13, 2022, after market close. The company will host a conference call to discuss the results that day at 4:30 P.M.